

HerResolve™ Endometriosis Diagnostic Test Result

PATIENT INFORMATION

Patient Name: Smith, Jane

DOB: 02/07/1992

Age: 34

Patient ID: AAA1111AAA111

LAB INFORMATION

Specimen Type: Whole Blood

Collection Date: 09/08/2026

Received Date: 09/11/2026

Report Date: 09/12/2026

Accession #: SAMPLE

PROVIDER INFORMATION

Ordering Provider: Winiarski, Steven

Practice Name: Instalab

Practice Address: 2261 Market St
Ste 10405

City, State, Zip: SAN FRANCISCO, CA, 94114

Practice Phone:

Practice Fax:

HerResolve™ / YOUR TEST RESULT

Endometriosis detected

ENDOMETRIOSIS DIAGNOSTIC TEST DESCRIPTION

HerResolve™ is a non-invasive diagnostic blood test designed to confirm the presence of endometriosis in symptomatic women. The test utilizes qPCR and immunochemistry methodologies in combination with an AI-driven algorithm to analyze the expression profile of specific microRNAs (miRNAs) and soluble proteins. These biomarkers are highly correlated with the pathophysiology of endometriosis.

CLINICAL VALIDATION

HerResolve™ has been validated in women 18-49 years of age who are experiencing symptoms suggestive of endometriosis. The validation population is comprised of patient samples collected prospectively from multiple sites. Validation data demonstrates non-inferiority to laparoscopy with histology. Test results have 98% specificity, 80% sensitivity, and 94% accuracy at time of blood draw. Menstrual phase, autoimmune disease, and treatment may impact test performance.



Laboratory Director: Owatha Tatum PhD, HCLD/CC(ABB), MBA

Date: 2026-09-12

This test was developed and its performance characteristics determined by HerAnova Lifesciences and MicroGen Diagnostics. It has not been cleared or approved by the US Foods and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This laboratory is certified under the Clinical Laboratory Improvement Amendments act of 1988 (CLIA-88) as qualified to perform high complexity clinical testing. Final diagnosis must be made by a healthcare professional after reviewing and interpreting the results in correlation with other relevant clinical information. Diagnosis should not be made solely from the results of this test. No final diagnosis is being made by HerAnova Lifesciences or MicroGen Diagnostics and neither organization shall be held liable for interpretation of the results, effects, or adverse events associated with subsequent treatment.

Disclaimers: A "not detected" test result does not definitively rule out endometriosis. 1,2,3 The HerResolve™ test does not rule in or rule out the presence of other gynecologic conditions. Test results may vary depending on adherence to sample storage and shipment instructions. As is standard in diagnostic testing, false positives and false negatives may occur.

1. ESHRE Endometriosis Guideline Development Group; 2022
2. NICE Guideline Endometriosis: diagnosis and management; 2024
3. ASRM Endometriosis and infertility: a committee opinion; 2012



HerAnova Lifesciences | MicroGen Diagnostics
6901 Quaker Ave, Suite 200, Lubbock, TX 79413

